UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 14, 2020

 

ACHIEVE LIFE SCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

 

033-80623

 

95-4343413

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 

1040 West Georgia, Suite 1030

Vancouver, B.C., Canada

 

V6E 4H1

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (604) 210-2217

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of exchange on which registered

Common Stock, par value $0.001 per share

ACHV

The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 

 


Item 2.02    Results of Operations and Financial Condition.

On May 14, 2020, Achieve Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2020. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.       

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Annual Meeting of Stockholders of the Company was held on May 12, 2020.  The following is a brief description of each matter voted upon and the certified voting results.

(1)Election of seven directors to serve until the Company’s next annual meeting or until the directors’ successors are duly elected and qualified:

 

 

 

For

 

 

Withhold

 

 

Broker
Non-Votes

 

Anthony Clarke

 

 

6,756,706

 

 

 

1,406,912

 

 

 

15,161,787

 

Scott Cormack

 

 

6,729,779

 

 

 

1,433,839

 

 

 

15,161,787

 

Donald Joseph

 

 

6,722,921

 

 

 

1,440,697

 

 

 

15,161,787

 

Martin Mattingly

 

 

6,954,521

 

 

 

1,209,097

 

 

 

15,161,787

 

Jay Moyes

 

 

6,737,294

 

 

 

1,426,324

 

 

 

15,161,787

 

Stewart Parker

 

 

6,910,194

 

 

 

1,253,424

 

 

 

15,161,787

 

Richard Stewart

 

 

6,773,709

 

 

 

1,389,909

 

 

 

15,161,787

 

Pursuant to the foregoing votes, the nominees listed above were elected as directors to serve on the Company’s board of directors.

(2)Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020:

 

For

 

 

Against

 

 

Abstain

 

 

Broker
Non-votes

 

19,519,689

 

 

 

 

3,311,533

 

 

494,183

 

 

 

 

 

Pursuant to the foregoing votes, the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020 was ratified.

(3)Approval of an amendment to the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split by a ratio not to exceed 1-for-20:

 

For

 

 

Against

 

 

Abstain

 

 

Broker
Non-votes

 

15,892,238

 

 

 

7,376,787

 

 

 

56,380

 

 

 

 

 

Pursuant to the foregoing votes, this matter was approved.

 


(4)Approval of an amendment of the Company’s 2018 Equity Incentive Plan to increase the number of shares available for issuance thereunder:

 

For

 

 

Against

 

 

Abstain

 

 

Broker
Non-votes

 

5,126,941

 

 

 

2,926,614

 

 

 

110,063

 

 

 

15,161,787

 

 

Pursuant to the foregoing votes, this matter was approved.

(5)Approval, by a non-binding advisory vote, the compensation paid by the Company to its Named Executive Officers:

 

For

 

 

Against

 

 

Abstain

 

 

Broker
Non-votes

 

5,795,068

 

 

 

2,205,275

 

 

 

163,275

 

 

 

15,161,787

 

 

Pursuant to the foregoing votes, this matter was approved.

 

Item 9.01.  Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

 

Description

 

 

 

99.1

 

 

 

Press release of Achieve Life Sciences, Inc. dated May 14, 2020

 

________________________

The information in Item 2.02 of this Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

________________________

 

 

 

 

 


 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

ACHIEVE LIFE SCIENCES, INC.

 

Date: May 14, 2020

 

/s/ John Bencich

 

John Bencich

Chief Financial and Operating Officer